Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
Researchers want to see if a single radiation therapy dose can limit the growth of colorectal cancer liver metastases. The people in this study have colorectal cancer that has metastasized (spread) to the liver. The treatment is called high-dose stereotactic body radiation therapy (SBRT).
Researchers want to see if giving NALIRIFOX chemotherapy with high-dose radiation therapy and capecitabine before surgery helps people with pancreatic cancer. The people in this study have pancreatic cancer that involves major blood vessels but has not spread to other organs. The study includes people with pancreatic cancer that may or may not be removable ("borderline resectable" or "locally advanced").
Researchers are comparing pembrolizumab given after surgery for head and neck cancer with the usual treatment. The usual therapy includes chemotherapy and radiation therapy. The people in this study have head and neck cancer that came back or is a new primary cancer.
The purpose of this study is to establish a registry to learn about neurocutaneous melanocytosis (NCM) and how people respond to treatments for this rare disease. NCM is seen mainly in children born with large dark-colored areas of skin called cutaneous melanocytic nevi (LCMN). About one in four of children with LCMN also develop NCM.
Skin (dermatologic) conditions are common in people who are receiving or have received cancer treatment. Sometimes the condition is related to the cancer, and sometimes it is related to cancer treatment. In either case, skin conditions can affect a person's quality of life.
Radiation therapy is one of the usual approaches to treating triple-negative breast cancer (TNBC). Researchers think that adding the immunotherapy drug pembrolizumab, with or without olaparib, to radiation therapy may be a better treatment for TNBC than radiation therapy alone.
In this study, researchers want to find the best dose of RGT-61159 to treat salivary gland cancer. The people in this study have adenoid cystic carcinoma that came back or keeps growing after treatment.
